Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
Status:
Completed
Trial end date:
2018-07-18
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose
combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and
treatment-experienced HIV-positive, adults with mild to moderate renal impairment.
Phase:
Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination